TRIOBP

Chr 22AR

TRIO and F-actin binding protein

Also known as: DFNB28, HRIHFB2122, TAP68, TARA, dJ37E16.4

This gene encodes a protein with an N-terminal pleckstrin homology domain and a C-terminal coiled-coil region. The protein interacts with trio, which is involved with neural tissue development and controlling actin cytoskeleton organization, cell motility and cell growth. The protein also associates with F-actin and stabilizes F-actin structures. Mutations in this gene have been associated with a form of autosomal recessive nonsyndromic deafness. Multiple alternatively spliced transcript variants that would encode different isoforms have been found for this gene, however some transcripts may be subject to nonsense-mediated decay (NMD). [provided by RefSeq, Nov 2008]

GeneReviewsOMIMResearchGenerating clinical summary…
MultiplemechanismARLOEUF 0.711 OMIM phenotype
Clinical SummaryTRIOBP
🧬
Gene-Disease Validity (ClinGen)
hearing loss, autosomal recessive · ARDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
68 unique Pathogenic / Likely Pathogenic· 318 VUS of 852 total submissions
📖
GeneReview available — TRIOBP
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?
0.71LOEUF
pLI 0.000
Z-score 4.07
OE 0.58 (0.470.71)
Tolerant

Typical tolerance to LoF variation

Missense Constraint?
-0.20Z-score
OE missense 1.01 (0.971.06)
1396 obs / 1375.5 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios?
LoF OE?0.58 (0.470.71)
00.351.4
Missense OE?1.01 (0.971.06)
00.61.4
Synonymous OE?0.94
01.21.6
LoF obs/exp: 63 / 108.8Missense obs/exp: 1396 / 1375.5Syn Z: 1.20

This gene — mechanism propensity

DN
0.6841th %ile
GOF
0.4973th %ile
LOF
0.4233th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and loss-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median
LOF99% of P/LP variants are LoF

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

ClinVar Variant Classifications

852 submitted variants in ClinVar

Classification Summary

Pathogenic35
Likely Pathogenic33
VUS318
Likely Benign299
Benign92
Conflicting47
35
Pathogenic
33
Likely Pathogenic
318
VUS
299
Likely Benign
92
Benign
47
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
35
0
0
0
35
Likely Pathogenic
32
1
0
0
33
VUS
5
286
17
10
318
Likely Benign
1
50
108
140
299
Benign
0
27
54
11
92
Conflicting
47
Total73364179161824

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

23 pathogenic / likely-pathogenic (of 25) ClinVar copy-number / structural variants overlap TRIOBP — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

TRIOBP · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →